Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study - PubMed (original) (raw)
Affiliations
- PMID: 2334534
Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study
J Atzpodien et al. Mol Biother. 1990 Mar.
Abstract
Recombinant interleukin-2 (rIL-2; EuroCetus, Amsterdam, Netherlands) was studied in an outpatient phase II trial in 14 patients with progressive metastatic renal carcinoma, malignant melanoma, and colorectal cancer. Escalating doses of rIL-2 were administered as subcutaneous bolus every 12 hours, starting at 0.3 million U/m2/d. A 100% dose increase occurred at weekly intervals, up to a maximum of 2.4 million U/m2/d. Responding patients or patients with stable disease after 4 weeks of rIL-2 (n = 9) were continued on maintenance therapy at 1.8 million U/m2 of rIL-2 administered once weekly. After 12 weeks of therapy, one renal cell cancer patient had a partial regression in lung metastases. Bolus injection of rIL-2 (1.2 million U/m2) resulted in peak serum levels of 25 to 30 U/ml. Toxicity of this regimen was moderate, with local inflammation at the injection sites, grade I-II (World Health Organization) malaise, nausea and/or vomiting, and fevers in 70% to 100% of patients treated. Thyroid dysfunction was observed in 10 patients receiving subcutaneous rIL-2; four of these patients had laboratory evidence of hyperthyroidism, and one had hypothyroidism. rIL-2-induced toxicity reversed spontaneously after cessation of treatment. In all patients receiving rIL-2, a dose-dependent increase in peripheral blood lymphocyte and eosinophil counts was noted, with a mean of 2.6 and 3.8 x 1,000/microliters after 4 weeks of therapy; mean lymphocyte and eosinophil counts were measured at 2.0 and 2.4 x 1,000/microliters in patients who received prior high-dose chemotherapy, compared with 3.2 and 5.1 x 1,000/microliters in those who did not.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
Kolitz JE, Wong GY, Welte K, Merluzzi VJ, Engert A, Bialas T, Polivka A, Bradley EC, Konrad M, Gnecco C, et al. Kolitz JE, et al. J Biol Response Mod. 1988 Oct;7(5):457-72. J Biol Response Mod. 1988. PMID: 3263471 - Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
Whitehead RP, Ward D, Hemingway L, Hemstreet GP 3rd, Bradley E, Konrad M. Whitehead RP, et al. Cancer Res. 1990 Oct 15;50(20):6708-15. Cancer Res. 1990. PMID: 2208137 - Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
Kirchner H, Körfer A, Palmer PA, Evers P, De Riese W, Knüver-Hopf J, Hadam M, Goldman U, Franks CR, Poliwoda H, et al. Kirchner H, et al. Mol Biother. 1990 Sep;2(3):145-54. Mol Biother. 1990. PMID: 2222898 - Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Sosman J, Lotze M, Gordon M, Logan T, Mier J. Dutcher JP, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S73-8. Cancer J Sci Am. 1997. PMID: 9457399 Review. - Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study.
Velotti F, Tubaro A, Stoppacciaro A, Pettinato A, Morrone S, Bossola P, Napolitano T, Miano L, Ruco L, Piccoli M, et al. Velotti F, et al. Ann Ist Super Sanita. 1990;26(3-4):411-21. Ann Ist Super Sanita. 1990. PMID: 2091503 Review.
Cited by
- Cytokine-based biotherapy of gastrointestinal tumors.
Buer J, Kirchner H, Schomburg A, Schüler A, Manns M, Lopez-Hänninen E, Duensing S, Poliwoda H, Atzpodien J. Buer J, et al. Clin Investig. 1994 Jul;72(7):526-34. doi: 10.1007/BF00207483. Clin Investig. 1994. PMID: 7981582 Review. - Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
Ravaud A, Négrier S, Cany L, Merrouche Y, Le Guillou M, Blay JY, Clavel M, Gaston R, Oskam R, Philip T. Ravaud A, et al. Br J Cancer. 1994 Jun;69(6):1111-4. doi: 10.1038/bjc.1994.218. Br J Cancer. 1994. PMID: 8198979 Free PMC article. Clinical Trial. - Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.
Eisenthal A, Skornick Y, Ron I, Zakuth V, Chaitchik S. Eisenthal A, et al. Cancer Immunol Immunother. 1993 Nov;37(6):367-72. doi: 10.1007/BF01526792. Cancer Immunol Immunother. 1993. PMID: 8242661 Free PMC article. - Phase II study of low dose cyclophosphamide and intravenous interleukin-2 in metastatic renal cancer.
Quan WD Jr, Dean GE, Lieskovsky G, Mitchell MS, Kempf RA. Quan WD Jr, et al. Invest New Drugs. 1994;12(1):35-9. doi: 10.1007/BF00873233. Invest New Drugs. 1994. PMID: 7960603 Clinical Trial. - Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Yee C, et al. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73. doi: 10.1073/pnas.242600099. Epub 2002 Nov 11. Proc Natl Acad Sci U S A. 2002. PMID: 12427970 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources